Evergreen With Envy: Halozyme’s Subcutaneous Conversions Grow As Rivals Hope To Break In

 
• By Bridget Silverman

Halozyme’s Enhanze technology has now brought seven monoclonal antibodies, including Ocrevus and Tecentriq, from IV to subcutaneous delivery, but Alteogen and other high-concentration formulation players hope to join the party as Medicare pricing issues help drive interest.

sparkling evergreen tree
With two recent approvals, subcutaneous conversions continue to sparkle as line extensions for established products. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers